全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
Core Evidence  2011 

Plerixafor for autologous CD34+ cell mobilization

DOI: http://dx.doi.org/10.2147/CE.S7801

Keywords: plerixafor, autologous hematopoietic cell transplant, CD34, lymphoma, myeloma, granulocyte colony-stimulating factor (G-CSF)

Full-Text   Cite this paper   Add to My Lib

Abstract:

ixafor for autologous CD34+ cell mobilization Review (3887) Total Article Views Authors: Huda Salman, Hillard M Lazarus Published Date February 2011 Volume 2011:6 Pages 23 - 29 DOI: http://dx.doi.org/10.2147/CE.S7801 Huda Salman, Hillard M Lazarus Division of Hematology-Oncology, Blood and Marrow Transplant Program, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA Abstract: High-dose chemotherapy and autologous transplantation of hematopoietic cells is a crucial treatment option for hematologic malignancy patients. Current mobilization regimes often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse events and produces significantly greater numbers of CD34+ cells when compared to G-CSF alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic cell transplant and in other disease targets.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133